文献速递肝病消化道肿瘤与早癌

高通量筛选发现抑制氧化磷酸化可选择性降低SALL4高表达肝癌细胞活力

New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation.
PubMed 文献 · Gastroenterology · 2019-08-22

研究建立高通量筛选平台,使用SNU-387和SNU-398肝癌细胞系及SALL4高低表达工程细胞,筛选1597种小分子和21575种天然产物提取物,发现PI-103及oligomycin等4种天然化合物类似物选择性降低SALL4hi细胞活力,其中4种抑制氧化磷酸化。Oligomycin对SALL4hi异种移植瘤生长的抑制作用大于sorafenib,对SALL4lo PDX肿瘤作用小,且对小鼠无毒性。SALL4结合约50%线粒体基因并激活其转录,增加氧化磷酸化、耗氧率、线粒体膜电位和ATP生成。

要点

  • 筛选发现oligomycin等氧化磷酸化抑制剂选择性降低SALL4hi肝癌细胞活力。
  • Oligomycin抑制SALL4hi异种移植瘤生长强于sorafenib,对SALL4lo PDX肿瘤作用小。
  • SALL4结合约50%线粒体基因,激活氧化磷酸化相关基因转录。

核心结论

  • 筛选降低SALL4高表达细胞活力的化合物,鉴定出氧化磷酸化抑制剂,可减缓小鼠SALL4hi细胞异种移植瘤生长。

研究设计与样本

  • 高通量筛选平台包含未修饰SNU-387和SNU-398肝癌细胞系及工程化表达低/高水平SALL4的SNU-387细胞系。
  • 筛选1597种药理活性小分子和21575种来自植物、细菌和真菌的天然产物提取物。
  • 异种移植瘤在NOD/SCID gamma小鼠中由SALL4hi SNU-398或HCC26.1细胞或SALL4lo患者来源异种移植(PDX)细胞生长,注射化合物或sorafenib后测量肿瘤生长效果。

主要发现

  • 筛选鉴定出1种小分子PI-103和4种天然化合物类似物(oligomycin、efrapeptin、antimycin、leucinostatin)选择性降低SALL4hi细胞活力。
  • 验证研究中4种化合物抑制氧化磷酸化。
  • ATP合酶抑制剂oligomycin降低SALL4hi肝细胞癌和非小细胞肺癌细胞系活力,对SALL4lo细胞影响极小。
  • Oligomycin抑制SALL4hi SNU-398或HCC26.1细胞异种移植瘤生长的程度大于sorafenib,但对SALL4lo PDX细胞生长的肿瘤作用小。
  • Oligomycin对小鼠无毒性。

关键数值与推荐

  • 染色质免疫沉淀测序分析显示SALL4结合约50%线粒体基因,包括许多氧化磷酸化基因,激活其转录。
  • 比较SALL4hi与SALL4敲低细胞,发现SALL4增加氧化磷酸化、耗氧率、线粒体膜电位及利用氧化磷酸化相关代谢物生成ATP。

临床怎么用

  • 氧化磷酸化抑制剂可能用于治疗SALL4高表达的肝脏肿瘤。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Some oncogenes encode transcription factors, but few drugs have been successfully developed to block their activity specifically in cancer cells. The transcription factor SALL4 is aberrantly expressed in solid tumor and leukemia cells. We developed a screen to identify compounds that reduce the viability of liver cancer cells that express high levels of SALL4, and we investigated their mechanisms. METHODS: We developed a stringent high-throughput screening platform comprising unmodified SNU-387 and SNU-398 liver cancer cell lines and SNU-387 cell lines engineered to express low and high levels of SALL4. We screened 1597 pharmacologically active small molecules and 21,575 natural product extracts from plant, bacteria, and fungal sources for those that selectively reduce the viability of cells with high levels of SALL4 (SALL4hi cells). We compared gene expression patterns of SALL4hi cells vs SALL4-knockdown cells using RNA sequencing and real-time polymerase chain reaction analyses. Xenograft tumors were grown in NOD/SCID gamma mice from SALL4hi SNU-398 or HCC26.1 cells or from SALL4lo patient-derived xenograft (PDX) cells; mice were given injections of identified compounds or sorafenib, and the effects on tumor growth were measured. RESULTS: Our screening identified 1 small molecule (PI-103) and 4 natural compound analogues (oligomycin, efrapeptin, antimycin, and leucinostatin) that selectively reduced viability of SALL4hi cells. We performed validation studies, and 4 of these compounds were found to inhibit oxidative phosphorylation. The adenosine triphosphate (ATP) synthase inhibitor oligomycin reduced the viability of SALL4hi hepatocellular carcinoma and non-small-cell lung cancer cell lines with minimal effects on SALL4lo cells. Oligomycin also reduced the growth of xenograft tumors grown from SALL4hi SNU-398 or HCC26.1 cells to a greater extent than sorafenib, but oligomycin had little effect on tumors grown from SALL4lo PDX cells. Oligomycin was not toxic to mice. Analyses of chromatin immunoprecipitation sequencing data showed that SALL4 binds approximately 50% of mitochondrial genes, including many oxidative phosphorylation genes, to activate their transcription. In comparing SALL4hi and SALL4-knockdown cells, we found SALL4 to increase oxidative phosphorylation, oxygen consumption rate, mitochondrial membrane potential, and use of oxidative phosphorylation-related metabolites to generate ATP. CONCLUSIONS: In a screening for compounds that reduce the viability of cells that express high levels of the transcription factor SALL4, we identified inhibitors of oxidative phosphorylation, which slowed the growth of xenograft tumors from SALL4hi cells in mice. SALL4 activates the transcription of genes that regulate oxidative phosphorylation to increase oxygen consumption, mitochondrial membrane potential, and ATP generation in cancer cells. Inhibitors of oxidative phosphorylation might be used for the treatment of liver tumors with high levels of SALL4.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Tan JL, Li F, Yeo JZ, et al. New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. Gastroenterology. 2019. PMID: 31446059. doi:10.1053/j.gastro.2019.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。